Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell-specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1-deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 can be expressed on some myeloid cells as well, and changes in the myeloid compartment could lead to an influx of inflammatory cells into various, distant tissues/organs and inciting organ damage”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Strauss et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“However, similar to its role in infections, PD-1 expression inversely correlates with M1 polarization and phagocytic potency of tumor-associated M (TAM) against tumor (7, 8).”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 2×
“Myeloid-specific PD-1 ablation induces improved T cell functionality Previously, it was determined that monocyte/macrophage terminal differentiation is controlled by the combined actions of retinoid receptors and the nuclear receptor peroxisome proliferator–activated receptor (PPAR), which is regulated by cholester…”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Cited by
Items 301–400 of 459
Miyahira, A. K., Zarif, J. C., Coombs, C. C., Flavell, R. R., Russo, J. W., Zaidi, S., Zhao, D., Zhao, S. G., Pienta, K. J., & Soule, H. R. (2021) · The Prostate · doi:10.1002/pros.24262 · Cited by 8
“Moreover, myeloid cells from tumor‐bearing PD‐1 mice lacked immune‐suppressive function as evidenced by lack of nitric oxide secretion and inability to suppress proliferation of ovalbumin‐specific T cells.(95) To study the role of PD1 specifically in myeloid cells, mice with PD‐1 deletion in the myeloid compartment we…”
BackgroundResultInfluentialImmune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8
“PD-1 de fi ciency could potentially increase cholesterol synthesis via gene regulation [85].”
BackgroundEvolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 10
Aged glomeruli: a link between PD-1 and podocytes
Yu, S. M.-W., & He, C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162330 · Cited by 8
“PD-1 is also expressed on myeloid cells, and previous data suggested that the myeloid cell-specific deletion of PD-1 or anti-PD-1 antibody induces monocytic lineage differentiation into macrophages (CD11b+F4/80+) (15).”
BackgroundImmunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy
Hofbauer, J., Hauck, A., Matos, C., Babl, N., Decking, S.-M., Rechenmacher, M., Schulz, C. K. J., Regotta, S., Mickler, M., Haferkamp, S., et al. (2022) · Biomolecules · doi:10.3390/biom12050716 · Cited by 9
“Combined scores should be validated for well-defined patient populations and further investigated in larger trials.”
Lee, L. H., Xu, X., Mourikis, T. P., Tang, F., Fairchild, L., Ji, L., Grauel, A. L., Wagner, J. P., Szpakowski, S., Pelletier, M. R., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0605 · Cited by 8
Wu, M.-M., Yang, Y.-C., Hu, Z., Chang, J.-Y., Xiao, H., Miao, C., Zhang, B.-W., He, Z.-X., Zhu, D., Duan, Y.-R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.009 · Cited by 7
Self-citationBenito-Lopez, J. J., Marroquin-Muciño, M., Perez-Medina, M., Chavez-Dominguez, R., Aguilar‐Cázares, D., Galicia-Velasco, M., & López-González, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1101503 · Cited by 7
Tritz, Z. P., Ayasoufi, K., Wolf, D. M., Owens, C. A., Malo, C. S., Himes, B. T., Fain, C. E., Goddery, E. N., Yokanovich, L. T., Jin, F., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0570 · Cited by 8
Chen, J., Liu, S., Ruan, Z., Wang, K., Xi, X., & Mao, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101220 · Cited by 8
Rosnev, S., Sterner, B., Schiele, P., Kolling, S., Martin, M., Flörcken, A., Erber, B., Wittenbecher, F., Kofla, G., Kurreck, A., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115252 · Cited by 7
Fick, K., Kerns, N., Zhao, Y., Tiamiyu, Z. A., Poschel, D. B., Czabala, P., Yang, D., Tang, Y., Xie, J., Fesenkova, V. I., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011415 · Cited by 7
Lutz, M. B., & Eckert, I. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104347 · Cited by 8
Do macrophages follow the beat of circadian rhythm in TIME (Tumor Immune Microenvironment)?
Knudsen-Clark, A. M., Cazarin, J., & Altman, B. J. (2023) · F1000Research · doi:10.12688/f1000research.129863.1 · Cited by 7
“Expression of PD-1 by TAMs has been shown to promote tumor progression by facilitating induction of oxidative metabolism that supports pro-tumorigenic and anti-inflammatory functions.(86) As such, PD-1+ TAMs expressed high levels of CD206, ARG1 and IL-10, relative to their PD-1 counterparts.”
BackgroundCardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
L'Orphelin, J. ‐., Dollalille, C., Akroun, J., Alexandre, J., & Dompmartin, A. (2023) · Cancers · doi:10.3390/cancers15072170 · Cited by 8
“In [25], an animal model carrying a myeloid cell-specific PD-1 ablation implicated in the anti-tumor immune response by effector myeloid cells underlined that PD-1-deficient mice synthesized more cholesterol by glycolysis mechanism alteration.”
BackgroundZhang, H., Zhu, L., Xie, Q., Zhang, L., Liu, J., Feng, Y.-Y.-F., Chen, Z.-K., Xia, H.-F., Fu, Q.-Y., Yu, Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114903 · Cited by 7
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
Park, B. J., Lee, A., Ye, F., Turker, I., & Johnson, D. B. (2022) · BMC Cancer · doi:10.1186/s12885-022-10090-9 · Cited by 7
“Within the context of ICIs, the blockade of the PD-1/L1 pathways has been associated not only with anti-tumor T cell responses, but with proatherogenic T-cell responses, the upregulation of genes involved in cholesterol synthesis, and a resulting increase in cellular cholesterol levels [6, 13].”
BackgroundInnate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets
Campesato, L. F., Weng, C., & Merghoub, T. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1816 · Cited by 7
“Although the paper focuses on crosstalk between tumor cells and macrophages and made use of more simplified systems to address CD24 signalling through Singlec-10, it is increasingly clear how the adaptive immune system influences innate immune function, by means of cytokine/ chemokine secretion and inhibitory/stimulat…”
BackgroundDaytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas
Ahmari, N., Choi, K., Wu, J., Rizvi, T. A., Jackson, M., Kershner, L. J., Kim, M., Zhang, X., Dombi, E., Shern, J. F., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202503359 · Cited by 6
“Myeloid-specific PD-1 ablation changes the fate of myeloid cells, alters T-cell phenotype, and modulates tumor growth (Strauss et al, 2020; Christofides et al, 2023).”
Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
Khalili, S., Zeinali, F., Fard, A. M., Taha, S. R., Naghibi, A. F., Bagheri, K., Zadeh, M. S., Eslami, Y., Fattah, K., Asadimanesh, N., et al. (2023) · Cancers · doi:10.3390/cancers15143722 · Cited by 6
“Interestingly, the expressed PD1 on TAMs has a contrariwise correlation with their ability to phagocytose tumor cells [198,199].”
BackgroundAo, X., Yang, Y., Okiji, T., Azuma, M., & Nagai, S. (2021) · Infection and Immunity · doi:10.1128/iai.00771-20 · Cited by 6
“In antitumor immunity, PD-1 regulates the metabolism-driven lineage fate commitment of myeloid progenitors and differentiation of effector myeloid cells (17).”
BackgroundZalba, S., Belsúe, V., Topp, B. G., de Alwis, D. P., Álvarez, M., Trocóniz, I. F., Berraondo, P., & Garrido, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01239-z · Cited by 7
Buj, R., Cole, A. R., Danielson, J., Xu, J. P., Hurd, D. E., Kishore, A., Kedziora, K. M., Chen, J., Yang, B., Barras, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.637227 · Cited by 8
Kalathoor, S., Rajendran, S. H., Canella, A., Raval, R. R., Cripe, T. P., Mardis, E. R., & Rajappa, P. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.578009 · Cited by 5
Dong, Y., Zhang, C., Mao, F., Dan, H., Zeng, X., Ji, N., Li, J., Chen, Q., Zhou, Y., & Li, T. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23670 · Cited by 5
“32 From the above results, it can be inferred that PD1 blockade could improve both antigen ‐ presentation and direct killing of cancer cells.”
BackgroundAssociation between Metabolic Reprogramming and Immune Regulation in Digestive Tract Tumors
Liu, J., Wang, T., Zhang, W., Huang, Y., Wang, X., & Li, Q. (2024) · Oncology Research and Treatment · doi:10.1159/000538659 · Cited by 5
“Interestingly, Strauss et al. [94] suggested that speci fi c ablation of PD-1 on MDSCs rather than T cells was more effective in suppressing tumor growth, and offered that emergency myelopoiesis metabolic reprogramming and effector myeloid cell differentiation played a major role in anti-tumor…”
BackgroundTargeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor
Chen, K. M., Grun, D., Gautier, B., Venkatesha, S. H., Maddox, M., Zhang, A.-H., & Andersen, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1380065 · Cited by 5
“Notably, while the programmed cell death protein 1 (PD-1) is best known as the immune checkpoint receptor expressed on activated T cells, PD-1 expression is associated with TAMs as well (7), indicating that PD-1/PD-L1 checkpoint therapy may exert its effect, in part, via TAMs (7, 8).”
BackgroundWang, Y., Dong, Q., Yuan, M., Hu, J., Lin, P., Yan, Y., Yan, Y., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113892 · Cited by 5
Self-citationPD-1 agonist: A novel therapeutic approach to resolve atherosclerosis
Chen, J., Yu, W., Liao, L., Fu, L., & Yang, P. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101892 · Cited by 5
Gestational colorectal cancer: Mechanisms, treatments, and prognosis
Ge, X., Feng, Y., Tan, S., Mao, W. B., Wang, Y., Zhu, J. Y., & Chen, Q. (2025) · International Journal of Cancer · doi:10.1002/ijc.35425 · Cited by 5
“15 Secondly, the abundance of MDSCs generates large amounts of reactive oxygen species to antagonize the proliferation of effector lymphocytes.”
Bird, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0276-7 · Cited by 5
Anufrieva, K. S., Shahriari, N., Gao, C., Yiu, S. P. T., Kazerounian, S., Castillo, R. L., Liu, J., Prell, S. A., Bhamidipati, K., Afshari, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74871-7 · Cited by 4
“While the functional role of these interactions in autoimmune skin disease remains unclear, the observed colocalization of PD-L1 -expressing mregDCs and activated Tregs may re fl ect anattempt to establish local immune regulationthat is insuf fi cient to fully suppress chronic in fl ammation 52 – 54 .”
Matsumoto, R., Tanoue, K., Nakayama, C., Okawa, M., Hozaka, Y., Idichi, T., Mataki, Y., & Ohtsuka, T. (2025) · Cancers · doi:10.3390/cancers17183090 · Cited by 4
“PD-1 expressed on TAMs is inversely correlated with the ability to phagocytose tumor cells [107,108], and high expression of co-inhibitory molecules such as PD-L1 and B7-H4 on TAMs suppresses ICI therapy in various tumors [105,109,110].”
Tang, Z., Huang, T., & Yang, T.-L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311596 · Cited by 5
“This reduction occurs through direct effects, like antibody-dependent cellular cytotoxicity, and indirect effects, such as IFN-γ - mediated differentiation into less suppressive myeloid cells [99].”
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Zhou, X., Geyer, F. K., Takimoto, J., Kolmar, H., & Rabinovich, B. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1718321 · Cited by 4
Gut microbiota and metabolic control of immune checkpoint blockade in cancer
Gladstone, J. L., & Sonnenberg, G. F. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.018 · Cited by 4
Wang, Z., See, X. Y., Chiang, C., Chang, Y.-C., Hsia, Y. P., Chiang, C., Peng, C., & Chiang, C. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2290348 · Cited by 4
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Boumpas, A., Papaioannou, A., Bousounis, P., Grigoriou, M., Bergo, V., Papafragkos, I., Tasis, A., Iskas, M., Boon, L., Makridakis, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386838 · Cited by 4
“Accordingly, ablation of the PD-L1/PD-1 axis changed the balance of myeloid cells exiting the BM with reduced MDSCs and increased effector myeloid cell frequencies (37).”
BackgroundInfluentialBarrio‐Alonso, C., Nieto‐Valle, A., Barandalla-Revilla, L., Avilés-Izquierdo, J. A., Parra‐Blanco, V., Sánchez‐Mateos, P., & Samaniego, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587545 · Cited by 4
Ponce, L. F., León, K., & Valiente, P. A. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c09463 · Cited by 4
PD1 Blockade in Cancer: Impact on Myeloid Cells
Fujiwara, M., Garo, L. P., & Murugaiyan, G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.018 · Cited by 4
MerTK Blockade Fuels Anti-tumor Immunity.
Blander, J. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.015 · Cited by 3
García-Vicente, L., Borja, M., Tran, V., Álvarez-Vázquez, A., Flores-Hernández, R., Granados, A. A., McGeever, A., Kim, Y.-J., Dorman, L. C., Detweiler, A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.26.564166 · Cited by 4
“Checkpoint ligands were expressed by tumor cells and immune cells, accordingly with recent studies that show the expression of checkpoint molecules by myeloid cells 47,62 .”
BackgroundGong, H., Griffin, J. D., Groer, C. E., Wu, X., Li, M., Abdelaziz, M. M., Xu, L., Forrest, M. L., & Berkland, C. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01798-9 · Cited by 3
“Blocking these through CPI might lead to enhanced T or NK cell activation and favorably skew the fraction of exhausted cells [63].”
Semitekolou, M., Paschalidis, N., Tartaro, D. L., Tsitsopoulou, A., Stamou, P., Mavroudis, A., Markaki, E., Varveri, A., Morianos, I., Lavigne, M. D., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112804 · Cited by 3
Jiang, X., Wu, H., Yan, N., Wu, A., Wang, X., Wen, Y., An, J., Chen, J., Yan, J., Wang, C., et al. (2025) · Research · doi:10.34133/research.1002 · Cited by 4
“Another possibility is that MDSCs express PD-1 [ 97 , 98 ], and anti-PD-1 treatment may induce enhanced activation of extracellular signal-regulated kinase (ERK1/2), mTORC1, and signal transducer and activator of transcription 1 (STAT1) in GMPs, which serve critical roles in myeloid cell…”
Yu, Z., Xu, Y., Li, W., Hu, Y., & Zhang, C. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00622 · Cited by 3
“26,27 This engagement suppresses downstream T-cell receptor and CD28 signaling cascades, leading to the functional impairment or exhaustion of T-cell effector functions and facilitating tumor immune evasion (Fig.”
Yang, Y., Mandt, T., Mittelstein, D. R., Das, M., Wu, P., Ghani, M. A., Illindala, R., Steinmetz, N. F., Burgoyne, A., Berman, Z. T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04286-8 · Cited by 3
“Exhausted CTLs express higher PD-1 which may bind to PD-L1 and enhance MDSC survival and proliferation [36], forming a feedback loop that sustains immunosuppression.”
Unraveling the immune microenvironment in primary CNS lymphoma
Lorenzen, S., Zeremski, V., Berisha, M., Mougiakakos, D., & Haage, T. R. (2026) · Biomarker Research · doi:10.1186/s40364-026-00945-9 · Cited by 3
“TAMs have been shown to express both, PD-1 and programmed death-ligand 1 (PD-L1, CD274) [45–47].”
[Cholesterol Metabolism and Tumor Immunity].
Luo, N., Shi, R., Dai, R., & Miao, H. (2022) · PubMed Central · doi:10.12182/20220360202 · Cited by 4
Raghani, R. M., Urie, R. R., Ma, J. A., Escalona, G., Schrack, I. A., DiLillo, K. M., Kandagatla, P., Decker, J. T., Morris, A. H., Arnold, K. B., et al. (2024) · ImmunoMedicine · doi:10.1002/imed.1052 · Cited by 3
Basic cancer immunology for radiation oncologists
Sia, J., Neeson, P. J., & Haynes, N. M. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13406 · Cited by 4
“For example, the surprising and perplexing role of PD-1 on myeloid cells (rather than T cells) has been inferred using pre-clinical models.(18) In”
Role of innate lymphoid cells in cancer metastasis
Moreno-Vicente, J., & Halim, T. Y. F. (2023) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2023.106465 · Cited by 3
Macrophages dig into the obesity paradox in cancer
Nabel, C. S., Gourgue, F., & Heiden, M. G. V. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.013 · Cited by 3
Understanding innate immune response in glioblastoma in search of a way forward
Pant, A., & Lim, M. K. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa038 · Cited by 4
Gestationally-Dependent Immune Organization at the Maternal-Fetal InterfacePreprint
Moore, A. R., Gonzalez, N. V., Plummer, K. A., Mitchel, O. R., Kaur, H., Rivera, M., Collica, B., Palmer, T. D., & Bendall, S. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.449807 · Cited by 3
Yeo, A. T., Shah, R., Aliazis, K., Pal, R., Xu, T., Zhang, P., Rawal, S., Rose, C. M., Varn, F. S., Appleman, V. A., et al. (2023) · doi:10.1158/2326-6066.c.6597334 · Cited by 3
Self-citationCan Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?
Delasos, L., Madabhushi, A., & Patil, P. D. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.011 · Cited by 6
Feng, X., Velázquez, G. F., Bohlscheid, S., Unterfrauner, M., Anand, P., Rejeski, H. A., Hartz, A. S., Baudrexler, T., Schmid, C., & Schmetzer, H. M. (2025) · Cancers · doi:10.3390/cancers17182948 · Cited by 2
“It is well known that the upregulation of PD1 on immune effector T-cells inhibits their effector function and promotes tumor progression, and that depletion of PD1-expressing T-cells enhances anti-tumor immunity [10,32].”
Qian, Y., Sun, Y., Wu, Y., Liu, Y., Zhou, X., Ning, H., Xiao, Y., Zhu, X., Zhou, X., Niu, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03115 · Cited by 2
PD-1 regulates latent effector differentiation of thymic cytotoxic CD8+ T cells
Mao, Z., Hirdler, J. B., Gicobi, J. K., Ding, L., Maynes, M. A., Hsu, M. A., Dellacecca, E. R., Zhang, W., Teske, J. J., Li, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73392-7 · Cited by 2
“Pdcd1 fl ox/ fl ox ( fl / fl ) mice on a C57BL/6 background were a kind gift from Dr. Vassiliki A. Boussiotis from Harvard Medical School, and the protocol for generating these mice has been previously described 37 .”
Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth
Bashir, H., Sanidad, K. Z., Ravisankar, P., Banks, K. M., Bose, A., Yu, S., McGrath, J. J. C., Carrow, H. C., Kim, T. K., Troxell, C. A., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.06.004 · Cited by 3
Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Achari, E., Ahmady, F., Sharma, A., Schmidt‐Wolf, I. G. H., Maciaczyk, J., Luwor, R. B., & Achuthan, A. A. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70144 · Cited by 2
Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination
Phares, T. W., Huang, J., Kotraiah, V., Hauser, M. J., Domi, A., Oruganti, S. R., Browne, C. D., Buontempo, P. J., Mansour, M., Pannucci, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1029636 · Cited by 2
“In addition to modifying T cell responses there is a growing body of literature demonstrating PD-1 expression on myeloid cells mediates cellular dysfunction (Huang et al., 2009; Strauss et al., 2020; Phares et al., 2021).”
BackgroundOverexpression of PDL-1 is a risk factor for lymph node metastasis in cervical cancer
Analysa, A., Lestari, D. P. O., & Artha, I. G. A. (2023) · International journal of health & medical sciences · doi:10.21744/ijhms.v6n2.2104 · Cited by 2
Exploring the function of myeloid cells in promoting metastasis in head and neck cancer
Okwuone, D. D. D., Morgan, D., & Gan, G. N. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00208 · Cited by 2
Laurino, S., Russi, S., Omer, L. C., D’Angelo, A., Bozza, G., Gallucci, G., Falco, G., Roviello, G., & Bochicchio, A. M. (2024) · Diseases · doi:10.3390/diseases12030047 · Cited by 2
“Preclinical studies have shown that the targets of ICIs (CTLA-4, PD-1, LAG-3, and PD-L1) are proteins with a negative regulatory role in atherosclerosis [50].”
Background[Immune Checkpoints Mediate Tumor Immune Regulation through Metabolic Pathways].
Du, W., Tang, X., Zhou, Y., Li, M., Jin, Z., Dou, J., & Zhao, J. (2025) · PubMed Central · doi:10.3779/j.issn.1009-3419.2025.106.08 · Cited by 2
Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
Guérin, M. V., Régnier, F., Thoreau, M., Vimeux, L., Bénard, M., Dransart, E., Penny, H. L., Johannes, L., Trautmann, A., & Bercovici, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000996 · Cited by 2
Functional Analysis of Tumor-Infiltrating Myeloid Cells by Flow Cytometry and Adoptive Transfer
Nguyen, A., Salem, O., & Wan, Y. (2021) · Journal of Visualized Experiments · doi:10.3791/61511 · Cited by 2
Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients
Cole, K., Ly, Q. P., Hollingsworth, M. A., Cox, J. L., Fisher, K. W., Padussis, J. C., Foster, J. M., Vargas, L. M., & Talmadge, J. E. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108628 · Cited by 2
Carty, S. A., Murga‐Zamalloa, C., & Wilcox, R. A. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.007 · Cited by 2
Inhibitory innate receptors and their potential role in transplantation
Lima, K. R., Ribas, G. T., Riella, L. V., & Borges, T. J. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100776 · Cited by 2
Dissecting the immune cell landscape in hepatocellular carcinoma—are we understanding complexity?
Ocker, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.170 · Cited by 2
“In a recent publication, the role of PD-1 in contributing to anti-tumor immunity was demonstrated also in myeloid cells in mice (13).”
BackgroundPARP7 Suppresses Radiation-induced Necroptosis and Abscopal ImmunityPreprint
Gupta, G. P., Goddard, A. M., McDonald, S., Lerner, L. M., Finkelstein, M., Wang, Q., Gharibpoor, F., Cho, M.-G., Ellington, S. W., Sutcliffe, M. D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7881707/v1 · Cited by 2
“5p-r) 50,51 .”
Self-citationArleo, A., Montagner, A., Giovannini, C., Suzzi, F., Piscaglia, F., & Gramantieri, L. (2024) · Biomolecules · doi:10.3390/biom14121496 · Cited by 1
“Seminal studies on PD1 blockade have demonstrated how it dictates the antitumor immune response [171], with the role of innate immune response surpassing that of adaptive immunity, which tends to remain the primary focus of research.”
InfluentialMyeloid cells: key players in tumor microenvironments
Hua, Q., Li, Z., Weng, Y., Wu, Y., & Zheng, L. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1124-8 · Cited by 1
Myeloid PD ‐1 Regulates Astrocyte Development and Leads to Active Behaviours
Qin, J., Wang, C., Li, S., Wang, Y., He, T., Jiao, J., & Ji, F. (2025) · Cell Proliferation · doi:10.1111/cpr.70082 · Cited by 1
Xie, H., Lv, M., Qin, J., Wang, Y., Na, W., Liu, Y., & Chang, K. C. J. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199655 · Cited by 1
“Furthermore, PD-1 blockade may promote the proliferation of myeloid-derived suppressor cells (MDSCs) (Strauss et al., 2020), which could regulate the immune response in chronic HBV-infected patients via PD-1 induced IL-10; and they may also promote the induction of Tregs and exhausted CD8 + T cells…”
PD-1 blockade elicits a systemic immune response but not in the tumor of TNBC mice
Hong, X., Ma, M., Cui, H., Yang, X., Li, F., Chu, M., Ye, Y., Jiang, Z., Pei, L., Liu, S., et al. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025240 · Cited by 1
Механизмы резистентности к иммунотерапии при MSI фенотипе
Федянин, М. Ю. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-15-3s1-11-30 · Cited by 1
“…— через индуцированное IFN-γ повышение экспрессии иммунных контрольных точек и привлечение иммуносупрессивных стромальных клеток и миелоид-ных клеток (фибробластов, нейтрофилов, макрофагов) по градиентам цитокинов (CCL2, CCL7, VEGF, IL-10, TGFB, IL-17, G-CSF, GM–CSF, IL1B, CCL20) [19,20].”
Amer, B., & Manerkar, S. (2026) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1622 · Cited by 1
Evdokimova, V. E., Ruzanov, P., Gassmann, H., Hung, M., Zhang, Z., Ribeiro, A. S., Khoshgoo, N., Zheng, S., Pachva, M. C., Ringwalt, E. M., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117708 · Cited by 1
Kim, S. A., Nam, G., Bae, Y. R., Jha, S. K., Kim, S., Choi, Y., Lee, Y., Kwon, M., Jeong, C., Byun, Y., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100025 · Cited by 1
Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms
Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i1.2062 · Cited by 3
“instance, activation of naïve CD8 + T cells results in effector cytotoxic T lymphocytes, whereas stimulation of CD4 + T cells results in T helper cells (such as Th1, Th2, and Th17 cells), T follicular helper (TFH) cells, and Treg cells.”
BackgroundLiu, S., Li, J., Que, Z., Yu, P., & Tian, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.106.14 · Cited by 2
“…[10] 。当它被适当激活时,抗肿瘤的 M1 型 TAMs 保留了抗原呈递细胞的特性,包括高表达主要 组织相容性复合体 II 类( major histocompatibility complex 和 T 细胞免疫球蛋白黏蛋白 -3 ( T cell immunoglobulin and mucin domain 3, TIM-3 ) [12-17] ,在血管生成、细胞外基质 ( extracellular matrix, ECM )重塑、肿瘤细胞增殖、转移和 免疫抑制,以及对化疗和免疫治疗的耐药性等方面发挥着 重要作用 [18] 。 TAMs 的双向调节作用使它逐渐被研究者们 所关注。”
Machine learning strategies for identifying repurposed drugs for cancer therapy
Lim, H., & Xie, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00003-8 · Cited by 2
Laaker, C. J., Hsu, M., Madrid, A., Port, J. M., Vrba, S. M., Herbáth, M., Baenen, C. M., Kumar, M., Priyathilaka, T. T., Sándor, M., et al. (2026) · eLife · doi:10.7554/elife.110460 · Cited by 1
“Inversely, eliminating PD-1 in Pdcd1 KO, APCs exhibit an increased ability to activate T cells in a tumor model, resulting in better tumor control ( Strauss et al., 2020 ).”
Novel biomarkers for melanoma immunotherapy
Wong, N. M. A. (2020) · Minerva Access (University of Melbourne)
Dong, L., Chen, H., Jiang, F., & Zheng, X. (2021) · Research Square · doi:10.21203/rs.3.rs-210463/v1
The Divergent Role of Co-receptors and Cytokines in the Immune Response to Cancer and Self
Tucker, C. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Immune Dysregulation In Pancreatic Cancer
Huffman, A. P. (2020) · Scholarly Commons (University of Pennsylvania)
The immunoregulation of autoimmune diabetes
Hu, H. (2021) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/3sz5-xf29
Zhang, Y., Yuan, T., Li, Z., Luo, C., Wu, Y., Zhang, J., Zhang, X., & Fan, W. (2020) · Research Square · doi:10.21203/rs.3.rs-118222/v1
“Antigen-speci c immune memory is one of the distinct superiorities of tumor immunotherapy [40, 41].”
BackgroundQuarterly picks from the editors
(2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4950
Targeting the Immuno-Oncology Metabolism in Cancer
Tripathi, S. C., Fahrmann, J. F., & Amle, D. B. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_5
Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist
Carbone, A., Inno, A., Islas, F., & Maurea, N. (2022) · Current clinical pathology · doi:10.1007/978-3-030-97744-3_8
Smalley, I., Chen, Z., Phadke, M. A., Li, J., Yu, X., Wyatt, C. J., Evernden, B. R., Messina, J. L., Sarnaik, A. A., Sondak, V. K., et al. (2023) · doi:10.1158/1078-0432.22480995
Smalley, I., Chen, Z., Phadke, M. A., Li, J., Yu, X., Wyatt, C. J., Evernden, B. R., Messina, J. L., Sarnaik, A. A., Sondak, V. K., et al. (2023) · doi:10.1158/1078-0432.c.6530586
Carnevalli, L. S., Taylor, M. A., King, M., Coenen-Stass, A. M. L., Hughes, A. M., Bell, S., Proia, T. A., Wang, Y., Ramos‐Montoya, A., Wali, N., et al. (2023) · doi:10.1158/1535-7163.c.6543334.v1
Metadata
- Authors
- Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., & Boussiotis, V. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7183328
- OpenAlex
- W2997277554
- Cited by
- 437
- References
- 73
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 67 · 2023: 83 · 2022: 70 · 2021: 77 · 2020: 59
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA183605, P01CA142106, R01CA212605)
- National Institute of Allergy and Infectious Diseases (R56AI098129)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, myeloid cells, antitumor immunity, myeloid-derived suppressor cells, good manufacturing practices, emergency myelopoiesis, myeloid progenitor cells, cholesterol metabolism, metabolic reprogramming, macrophage differentiation, dendritic cell differentiation, anti-PD-1 therapy, tumor immunology
- MeSH terms
- Animals, Cell Differentiation, Colonic Neoplasms, Female, Male, Melanoma, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.